Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
To learn if the drug combination pirtobrutinib, venetoclax, and obinutuzumab can help to control relapsed CLL/SLL.
Epistemonikos ID: 7ad99dd261d9c926554a7dcbbee76567e396707f
First added on: May 14, 2025